First-in-human Evaluation Of A Novel Immunobiotic To Prevent Respiratory Infection
Funder
National Health and Medical Research Council
Funding Amount
$1,180,080.00
Summary
Respiratory infections are a leading cause of death and illness throughout the world. We have discovered a 'friendly' bacteria that can be applied up the nose to prevent ear infections and the 'flu in mice. We will now test this novel therapy in humans to check it is safe and that it stimulates the human immune system in the same way that it does in mice. This will provide essential information to conduct clinical trials, with the aim to produce a medicine that prevents respiratory infections.
Identifying The Microbiological Risk Factors For Acute Lower Respiratory Infection In Indigenous Children To Inform Future Intervention Strategies
Funder
National Health and Medical Research Council
Funding Amount
$495,745.00
Summary
Lung infections such as pneumonia are common in Indigenous children, and can lead to repeated hospitalisation and permanent lung damage. They are also an important cause of preventable death in children. This study will look at the role of bacteria and viruses in lung infections, and will inform interventions to reduce the burden and consequences of lung infections in Indigenous children.
Exploring The Haemagglutinin-neuraminidase Of Human Parainfluenza Virus
Funder
National Health and Medical Research Council
Funding Amount
$731,268.00
Summary
Respiratory diseases, for example croup, in children are caused in the main by human parainfluenza viruses (hPIVs). No vaccines or specific antiviral therapy against hPIV infections exist. This project targets an essential protein in the virus’ lifecycle. This project will produce compounds that block the protein’s function and may provide drug candidates for development. Furthermore the role of human host cell-associated carbohydrates in parainfluenza infection will be better understood.
Inhibition Of IFN-?/? By Human Metapneumovirus And The Induction Of Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$605,251.00
Summary
The newly isolated human metapneumovirus (hMPV) causes significant respiratory illness in infants, young children and the elderly. The virus can persist long-term and may predispose individuals to chronic lung disease. This proposal aims to determine the mechanisms by which hMPV infection causes respiratory disease, with a view to improving treatments and preventing disease.
Role Of Toll-like Receptor 7 In Rhinovirus-induced Asthma Exacerbation
Funder
National Health and Medical Research Council
Funding Amount
$697,248.00
Summary
One third of the annual asthma-related health care expenditure may be attributable to asthma-related hospitalisations. Even mild asthmatics experience severe exacerbations at a rate of almost one per year1 and those attacks can be fatal. Rhinovirus (RV) causes the majority of asthma exacerbations which may be linked to an impaired antiviral interferon (IFN) response in asthmatics. RV is sensed by Toll-like receptor (TLR) 7, but the role of this innate host defence pathway in regulating antiviral
Using Total Population Data To Describe The Characteristics Of Respiratory Infections In Order To Predict Future Epidemics And Recommend Vaccination Strategies For Western Australian Children
Funder
National Health and Medical Research Council
Funding Amount
$294,892.00
Summary
Respiratory infections are a major reason for children to go to hospital. I am an epidemiologist and I will be using previously collected and linked laboratory and hospital data from Western Australian children to better understand how these infections flow through the population over different seasons. I will then be able to predict future epidemics of respiratory infections and how different vaccine programs might have an impact in reducing how many children are affected by these infections.
Asthma causes wheeze and shortness of breath via airway narrowing, with asthma attacks commonly caused by virus infections. We plan to investigate how airway narrowing during an asthma attack decreases the body’s ability to fight off a viral infection, causing prolonged infection, worse asthma symptoms, more airway inflammation and long-term damage within the airways. We will attempt to use current and novel treatments to reverse these problems, and improve treatment for asthma.
Effect Of Anti-IgE Antibody On Immune System Responses And Short-term Outcome In Acute Asthma In Children
Funder
National Health and Medical Research Council
Funding Amount
$571,752.00
Summary
We plan to undertake a randomised, double-blind, placebo-controlled, clinical trial of anti-IgE antibody given at the time of an acute attack of asthma in children aged 6-12 years. The idea for this arose from our own novel data – IgE levels increase with the most common infection causing acute asthma. Given evidence the virus uses IgE to cause inflammation, giving anti-IgE during the attack should reduce the severity of the attack and produce a new, effective treatment for acute asthma.
Investigation Into Host Susceptibility And Immune Responses In Young Children With Acute Wheezing Due To Human Rhinovirus Group C Infection
Funder
National Health and Medical Research Council
Funding Amount
$682,711.00
Summary
We recently made the surprising discovery that a new viral group, human rhinovirus group C (HRV-C), causes the majority of acute asthma in children. We also found that it causes half of the acute wheezing attacks in younger children, and is the only respiratory virus associated with allergy. So, HRV-C may be the key to the relationship between allergy and asthma. The planned project will focus on whether young children who wheeze with HRV-C have related defects in their immune system.